review · Non-Coding RNA
Long intergenic non-coding RNAs, known as lincRNAs, play critical roles in cellular activities such as chromatin remodelling and gene expression control. Abnormal expression of these molecules can either promote or inhibit cancer development. Genetic variations within lincRNAs, including single nucleotide polymorphisms, can alter messenger RNA stability and overall gene expression, linking them to several cancer types. Among these molecules, LINC00511 specifically drives progression across several malignancies, including colorectal, lung, breast, and liver cancers. Because of its active involvement in tumour advancement, LINC00511 serves as a promising molecular marker for cancer prognosis and a candidate for targeted therapeutic intervention. Synthesising data from literature and computational databases highlights how these non-coding sequences and their genetic variants operate across varied biological pathways in diverse cancers.
Non-coding genetic material constitutes a major portion of the human genome and strongly influences disease. Understanding how specific molecules like LINC00511 and their genetic variants drive tumour development provides clinicians and biomedical researchers with new avenues for detecting aggressive cancers and tailoring treatments based on specific molecular profiles.
This work points towards potential applications in cancer diagnostics and therapeutics, specifically the development of prognostic biomarkers and targeted drug candidates based on LINC00511. The primary end users would be molecular diagnostic developers and oncology drug discovery teams. Because the findings are drawn from literature review and computational database searches, the research remains at an early exploratory stage, far from clinical deployment.
AI-generated from the published abstract. Always read the original work before citing.
BACKGROUND: Long intergenic non-coding RNA, is one type of lncRNA, exerting various cellular activities, as does ncRNA, including the regulation of gene expression and chromatin remodeling. The abnormal expression of lincRNAs can induce or suppress carcinogenesis. MAIN BODY: LincRNAs can regulate cancer progression through different mechanisms and are considered as potential drug targets. Genetic variations such as single nucleotide polymorphisms (SNPs) in lincRNAs may affect gene expression and messenger ribonucleic acid (mRNA) stability. SNPs in lincRNAs have been found to be associated with different types of cancer, as well. Specifically, LINC00511 has been known to promote the progression of multiple malignancies such as breast cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, and others, making it a promising cancer prognostic molecular marker. CONCLUSION: LincRNAs have been proved to be associated with different cancer types through various pathways. Herein, we performed a comprehensive literature and in silico databases search listing lncRNAs, lincRNAs including LINC00511, lncRNAs' SNPs, as well as LINC00511 SNPs in different cancer types, focusing on their role in various cancer types and mechanism(s) of action.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/ncrna9050058
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
